Review Article
Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics
Table 1
Function and expression of genes synthetically lethal with FA.
| Gene synthetically lethal with FA genes | Function | Expression in tumor cells |
| TREX2 [52] | DNA exonuclease; SAGA complex pathway | Expressed in most tumor cell lines [60] | PARP1 [52] | BER | Overexpressed in tumors, including medulloblastoma, ependymoma, HGG, melanoma, and breast cancers [35, 61ā63] | PLK1 [52] | Cell-cycle progression | Over-expressed in many human tumors [64] | RAD6/HR6B [52] | Switching of DNA polymerases | Upregulated in metastatic mammary tumors [65] | CDK7 [52] | Transcription | Moderately over-expressed in tumor cell lines [66] | TP53BP1 [52] | DSB sensing; ATM activation | Underexpressed in most cases of triple negative breast cancer [67] | ATM [52] | DSB response kinase | Under-expressed in some tumors, see Figure 3 | NEIL1 [52] | BER | Expression reduced in 46% of gastric cancers [68] | RAD54B [52] | HR | Known to be mutated in cancer cell lines [69, 70] | NBS1 [52] | DSB sensing; ATM activation | Over-expressed in HNSCC tumors [71] | ADH5 [6] | Formaldehyde processing | Reduced expression in melanoma cells [72] |
|
|